

# 2014 TCTAP

## Wrap-Up Interview

# LM and Bifurcation PCI

**Moderator**

**David E. Kandzari**

**Interviewees**

**Yves R. Louvard, Seung-Jung Park,  
David Paul Taggart**

# Issues in Briefs

## Left Main PCI

### 1. How To Do ?

Integrated Use of FFR and IVUS

Risk Stratification, SYNTAX Score ?

Single or Two Stent

What About BVS ?

### 2. CABG vs. PCI

Meta-analysis and EXCEL

### 3. Current and Future Guideline

# How To Do LM PCI ?

# Why FFR ?

---


- 1. Accurate Diagnosis First !**  
Angiographic Assessment is **Not Always Enough.**
- 2. There are Many Visual Functional Mismatches.**  
FFR is Crucial for Intermediate LM Ostial and Shaft Lesions.
- 3. Avoid Unnecessary Procedure is the Most Important Factor to Reduce Unfavorable Outcomes.**

# Why IVUS Too ?

- 1. IVUS Guidance Saves Lives.**
- 2. Assessment of LM Ostium, Reference Vessel Diameter, Pattern of Remodeling, and Vulnerability of Plaque.**
- 3. Treatment Strategy Would be Simplified as Single Stent Cross-Over Depending on the Disease Status of LCX Ostium by Separate IVUS Run.**
- 4. IVUS Guided Stent Optimization and Effective Stent CSA Can Make a Good Clinical Outcomes.**
- 5. Smaller IVUS MLA  $4.5 \text{ mm}^2$  Can Predict Functional Significance of LM Stenosis.**

# New LM IVUS MLA


Matched with FFR <0.80,  
Ostial and Shaft LM Disease (N=112)



**Cut-off = 4.5 mm<sup>2</sup>**


Sensitivity	79%
Specificity	80%
PPV	83%
NPV	76%
Accuracy	80%

# IVUS Stent Area to Reduce Restenosis (Rule of 5,6,7,8)




# Role of SYNTAX Score and Modifiers

## *In Risk Prediction and Treatment Selection*



# Restenosis at 2 year

Pooled Analysis in 403 Patients with LM PCI Using SES



# Single- VS. Two-stent

## Meta-analysis

### Stent Thrombosis



Favor 2-stent 1-stent

### TVR




Favor 2-stent 1-stent


# Bioresorbable BVS for Bifurcation

## Mini-Crush

## T-stenting with Ring Disruption



Arrow: deformed BVS





Arrow: disrupted BVS

# PCI vs. CABG

# PCI or CABG saves life for LM disease


## *Bayesian Net-work Meta-analysis*




# PCI VS. CABG

## 5-year Meta-analysis


### Mortality




### TVR



### Stroke



### MACCE



# EXCEL Randomized Study

2900 pts with unprotected left main disease

@ 165 international sites

SYNTAX score  $\leq 32$

Consensus agreement by heart team

Yes

(N=1900)

No

(N=1000)

Enrollment  
registry

R

PCI (Xience Prime)

(N=850)

CABG

(N=850)

Clinical follow-up: 1 mo, 6 mo and yearly through 5 years

Primary end point: death, MI or stroke

# ACC/AHA Guidelines 2011

## Elective PCI for LM Stenosis

I	IIa	IIb	III
	<b>B</b>		
		<b>B</b>	
			<b>B</b>

Low risk PCI, *SYNTAX* score  $\leq 22$   
or Ostial or Shaft LM  
High risk CABG ; STS risk  $\geq 5\%$


Intermediate-risk PCI, *SYNTAX* score  $< 33$   
or Bifurcation LM  
High risk CABG ; STS risk  $\geq 2\%$   
or COPD, Disabled Stroke, Redo CABG

Unfavorable Anatomy for PCI,  
but Good CABG Candidate

# ESC Guidelines 2011

## Elective PCI for LM Stenosis

I IIa IIb III



LM with isolated or 1 VD and ostial or shaft

LM with isolated or 1 VD and bifurcation LM  
LM with 2 or 3 VD & *SYNTAX score*  $\leq 32$

LM with 2 or 3 VD & *SYNTAX score*  $\geq 32$

# Discussion

## Left Main PCI

### 1. How To Do ?

Integrated Use of FFR and IVUS

Risk Stratification, SYNTAX Score ?

Single or Two Stent

What About BVS ?

### 2. CABG vs. PCI

Meta-analysis and EXCEL

### 3. Current and Future Guideline